keyword
MENU ▼
Read by QxMD icon Read
search

Ki67 breast cancer

keyword
https://www.readbyqxmd.com/read/28331745/correlations-between-oncotype-dx-recurrence-score-and-classic-risk-factors-in-early-breast-cancer-results-of-a-prospective-multicenter-study-in-turkey
#1
Vahit Özmen, Ajlan Atasoy, Erhan Gökmen, Mustafa Özdoğan, Nilufer Güler, Cihan Uras, Engin Ok, Orhan Demircan, Abdurrahman Işıkkdoğan, Neslihan Cabioğlu, Fatma Şen, Pınar Saip
OBJECTIVE: Breast cancer is the most common malignancy among Turkish women and the rate of early stage disease is increasing. The Oncotype DX 21-gene assay is predictive of distant recurrence in ER-positive, HER2-negative early breast cancer. We aimed to evaluate the correlations between Recurrence Score (RS) and routine risk factors. MATERIALS AND METHODS: Ten academic centers across Turkey participated in this prospective trial. Consecutive patients with breast cancer who had pT1-3, pN0-N1mic, ER-positive, and HER2-negative tumors were identified at tumor conferences...
July 2016: J Breast Health (2013)
https://www.readbyqxmd.com/read/28324268/a-phase-ii-study-of-combined-ridaforolimus-and-dalotuzumab-compared-with-exemestane-in-patients-with-estrogen-receptor-positive-breast-cancer
#2
José Baselga, Serafin M Morales, Ahmad Awada, Joanne L Blum, Antoinette R Tan, Marianne Ewertz, Javier Cortes, Beverly Moy, Kathryn J Ruddy, Tufia Haddad, Eva M Ciruelos, Peter Vuylsteke, Scot Ebbinghaus, Ellie Im, Lamar Eaton, Kumudu Pathiraja, Christine Gause, David Mauro, Mary Beth Jones, Hope S Rugo
PURPOSE: Combining the mTOR inhibitor ridaforolimus and the anti-IGFR antibody dalotuzumab demonstrated antitumor activity, including partial responses, in estrogen receptor (ER)-positive advanced breast cancer, especially in high proliferation tumors (Ki67 > 15%). METHODS: This randomized, multicenter, international, phase II study enrolled postmenopausal women with advanced ER-positive breast cancer previously treated with a nonsteroidal aromatase inhibitor (NCT01234857)...
March 21, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28315068/efficacy-and-safety-of-nab-paclitaxel-125%C3%A2-mg-m-2-and-nab-paclitaxel-150%C3%A2-mg-m-2-compared-to-paclitaxel-in-early-high-risk-breast-cancer-results-from-the-neoadjuvant-randomized-geparsepto-study-gbg-69
#3
Jenny Furlanetto, Christian Jackisch, Michael Untch, Andreas Schneeweiss, Sabine Schmatloch, Bahriye Aktas, Carsten Denkert, Hermann Wiebringhaus, Sherko Kümmel, Mathias Warm, Stefan Paepke, Marianne Just, Claus Hanusch, John Hackmann, Jens Uwe Blohmer, Michael Clemens, Serban Dan Costa, Bernd Gerber, Valentina Nekljudova, Sibylle Loibl, Gunter von Minckwitz
PURPOSE: The GeparSepto study demonstrated that the use of nab-paclitaxel instead of paclitaxel prior to anthracycline-based chemotherapy could lead to a significantly increased pCR rate, especially in the triple negative subpopulation. We report efficacy and safety for patients treated with two different doses of nab-paclitaxel in comparison to weekly solvent-formulated paclitaxel. METHODS: Patients were treated for 12 weeks with either intravenous nab-paclitaxel 150 mg/m(2) (nP150) weekly, after study amendment 125 mg/m(2) (nP125) weekly or solvent-based paclitaxel 80 mg/m(2) (P80) weekly followed by epirubicin 90 mg/m(2) and cyclophosphamide 600 mg/m(2) on day 1 for four 3-week cycles...
March 17, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28299888/the-relationship-of-race-oncotype-dx-and-ki67-in-a-population-highly-screened-for-breast-cancer
#4
Amber A Guth, Jennifer Chun Kim, Shira Schwartz, Jennifer Montes, Rebecca Akiko Snyder, Deborah Axelrod, Freya Schnabel
Oncotype DX recurrence score (ODX) can predict risk of invasive breast cancer recurrence and benefit of chemotherapy. Literature is limited on the relationship of ODX and race in women with hormone receptor positive and node negative/positive disease. Our study examines the relationship between race and clinical characteristics within a population of highly screened women with newly diagnosed breast cancer. The institutional Breast Cancer Database was queried for patients with newly diagnosed breast cancer between January2010 and March2015...
March 2017: Breast Journal
https://www.readbyqxmd.com/read/28294317/the-spectrum-of-brca-mutations-and-characteristics-of-brca-associated-breast-cancers-in-china-screening-of-2991-patients-and-1043-controls-by-next-generation-sequencing
#5
Guan-Tian Lang, Jin-Xiu Shi, Xin Hu, Chen-Hui Zhang, Ling Shan, Chuan-Gui Song, Zhi-Gang Zhuang, A-Yong Cao, Hong Ling, Ke-Da Yu, Li Shan, Meng-Hong Sun, Xiao-Yan Zhou, Wei Huang, Zhi-Ming Shao
To characterize the prevalence of BRCA mutations and characteristics of BRCA carriers in China and to update the clinical recommendations for BRCA testing, we conducted a wide screen for BRCA mutations using next-generation sequencing (NGS). A total of 4,034 Chinese subjects were screened for germline BRCA1/2 mutations, including 2,991 breast cancer patients and 1,043 healthy individuals from the community enrolled as controls. We developed an NGS-based approach to perform BRCA1/2 screening. BRCA mutations were identified in 9...
March 14, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/28289852/tumor-infiltrating-lymphocytes-and-molecular-response-after-neoadjuvant-therapy-for-hr-her2-%C3%A2-breast-cancer-results-from-two-prospective-trials
#6
M V Dieci, A Frassoldati, D Generali, G Bisagni, F Piacentini, L Cavanna, K Cagossi, F Puglisi, A Michelotti, R Berardi, G Banna, A Goubar, G Ficarra, G Griguolo, Pierfranco Conte, V Guarneri
PURPOSE: The aim was to evaluate the role of tumor-infiltrating lymphocytes (TIL) in predicting molecular response after preoperative endocrine or cytotoxic treatment for HR+/HER2- patients who do not achieve a pathological complete response. METHODS: Stromal (Str) TIL were centrally evaluated on samples from diagnostic core-biopsies of HR+/HER2- patients included in two prospective randomized trials: the LETLOB trial (neoadjuvant endocrine-based treatment) and the GIOB trial (neoadjuvant chemotherapy-based treatment)...
March 13, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28272000/study-of-serum-carcinoembryonic-antigen-s-profile-for-breast-cancer-in-western-algeria-100-cases
#7
Zenib Tahari, Asmahane Medjdoub, Tewfik Sahraoui, Leila Belhabri, Fatima Zohra El Kebir
BACKGROUND: Breast cancer is the most common cancer in women worldwide. Biology contributes to the early diagnosis and monitoring of breast cancer with several categories of markers such as prognostic markers (ER, PR, HER2), proliferative markers (Ki67), and tumor markers such as CEA and CA 15-3. CEA can be detected at a high concentration in serum of patients with malignant tumors. AIM: The aim of our study was to evaluate the concentrations of CEA in serum of women with breast cancer and to verify the existence of a possible link between the average rates of CEA and SBR grade...
January 2017: Gulf Journal of Oncology
https://www.readbyqxmd.com/read/28270498/a-randomized-phase-ii-neoadjuvant-study-of-cisplatin-paclitaxel-with-or-without-everolimus-in-patients-with-stage-ii-iii-triple-negative-breast-cancer-tnbc
#8
Bojana Jovanovic, Ingrid A Mayer, Erica L Mayer, Vandana G Abramson, Aditya Bardia, Melinda Sanders, Maria G Kuba, Monica Valeria Estrada, J Scott Beeler, Timothy M Shaver, Kimberly N Johnson, Violeta Sanchez, Jennifer M Rosenbluth, Patrick M Dillon, Andres Forrero-Torres, Jenny C Chang, Ingrid Meszoely, Ana Grau, Brian D Lehmann, Yu Shyr, Quanhu Sheng, Sheau-Chiann Chen, Carlos L Arteaga, Jennifer A Pietenpol
PURPOSE: Due to inherent disease heterogeneity, targeted therapies have eluded TNBC, and biomarkers predictive of treatment response have not yet been identified. This study was designed to determine if the mTOR inhibitor everolimus with cisplatin and paclitaxel would provide synergistic anti-tumor effects in TNBC. EXPERIMENTAL DESIGN: Stage II/III patients with TNBC were enrolled in a randomized phase II trial of preoperative weekly cisplatin, paclitaxel and daily everolimus or placebo for 12 weeks, until definitive surgery...
March 7, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28270497/neopalana-neoadjuvant-palbociclib-a-cyclin-dependent-kinase-4-6-inhibitor-and-anastrozole-for-clinical-stage-2-or-3-estrogen-receptor-positive-breast-cancer
#9
Cynthia X Ma, Feng Gao, Jingqin Luo, Donald W Northfelt, Matthew P Goetz, Andres Forero, Jeremy Hoog, Michael J Naughton, Foluso Ademuyiwa, Rama Suresh, Karen S Anderson, Julie Margenthaler, Rebecca Aft, Timothy J Hobday, Timothy Moynihan, William Gillanders, Amy Cyr, Timothy J Eberlein, Tina Hieken, Helen Krontiras, Zhanfang Guo, Michelle Lee, Nicholas C Spies, Zachary L Skidmore, Obi L Griffith, Malachi Griffith, Shana Thomas, Caroline Bumb, Kiran Vij, Cynthia Huang Bartlett, Maria Koehler, Hussam Al-Kateb, Souzan Sanati, Matthew J Ellis
PURPOSE: Cyclin-dependent kinase (CDK) 4/6 drives cell proliferation in estrogen receptor positive (ER+) breast cancer. This single-arm phase II neoadjuvant trial (NeoPalAna) assessed the anti-proliferative activity of the CDK4/6 inhibitor palbociclib in primary breast cancer as a prelude to adjuvant studies. EXPERIMENTAL DESIGN: Eligible patients with clinical stage II/III ER+/HER2- breast cancer received anastrozole 1mg daily for 4 weeks (cycle 0) (with goserelin if premenopausal), followed by adding palbociclib (125mg daily on days 1-21) on cycle 1 day 1 (C1D1) for four 28-day cycles unless C1D15 Ki67>10%, in which case patients went off study due to inadequately response...
March 7, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28270035/bmi-1-promotes-self-renewal-of-radio-and-temozolomide-tmz-resistant-breast-cancer-cells
#10
Yanfang Yan, Ying Wang, Pengxin Zhao, Weiyuan Ma, Zhigang Hu, Kaili Zhang
Breast cancer is a hormone-dependent malignancy and is the most prevalent cause of cancer-related mortality among females. Radiation therapy and chemotherapy are common treatments of breast cancer. However, tumor relapse and metastasis following therapy are major clinical challenges. The importance of B-lymphoma Moloney murine leukemia virus insertion region-1 (BMI-1) was implicated in cell proliferation, stem cell maintenance, and tumor initiation. We established radio- and temozolomide (TMZ)-resistant (IRC-R) MCF-7 and MDA-MB-231 cell lines to investigate the mechanism involved in therapeutic resistance...
January 1, 2017: Reproductive Sciences
https://www.readbyqxmd.com/read/28259011/clinical-use-of-biomarkers-in-breast-cancer-updated-guidelines-from-the-european-group-on-tumor-markers-egtm
#11
REVIEW
M J Duffy, N Harbeck, M Nap, R Molina, A Nicolini, E Senkus, F Cardoso
Biomarkers play an essential role in the management of patients with invasive breast cancer. For selecting patients likely to respond to endocrine therapy, both oestrogen receptors (ERs) and progesterone receptors (PRs) should be measured on all newly diagnosed invasive breast cancers. On the other hand, for selecting likely response to all forms of anti-HER2 therapy (trastuzumab, pertuzumab, lapatinib or ado-trastuzumab emtansine), determination of HER2 expression or gene copy number is mandatory. Where feasible, measurement of ER, PR and HER2 should be performed on recurrent lesions and the primary invasive tumour...
February 27, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28253895/ezh2-protein-expression-in-normal-breast-epithelium-and-risk-of-breast-cancer-results-from-the-nurses-health-studies
#12
Francisco Beca, Kevin Kensler, Benjamin Glass, Stuart J Schnitt, Rulla M Tamimi, Andrew H Beck
BACKGROUND: Enhancer of zeste homolog 2 (EZH2) is a polycomb-group protein that is involved in stem cell renewal and carcinogenesis. In breast cancer, increased EZH2 expression is associated with aggressiveness and has been suggested to identify normal breast epithelium at increased risk of breast cancer development. However, the association between EZH2 expression in benign breast tissue and breast cancer risk has not previously been evaluated in a large prospective cohort. METHODS: We examined the association between EZH2 protein expression and subsequent breast cancer risk using logistic regression in a nested case-control study of benign breast disease (BBD) and breast cancer within the Nurses' Health Studies...
March 2, 2017: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/28249942/quantifying-tumour-vascularity-in-non-luminal-breast-cancers
#13
Maria Ryssdal Kraby, Signe Opdahl, Lars A Akslen, Anna M Bofin
AIMS: Microvessel density (MVD), proliferating MVD (pMVD) and vascular proliferation index (VPI) are methods used to quantify tumour vascularity in histopathological sections. In this study, we assessed MVD, pMVD and VPI in non-luminal subtypes of breast cancer. Differences between subtypes were studied, and the prognostic value of each method was assessed. METHODS: All non-luminal subtypes (61 basal phenotype (BP), 60 human epidermal growth factor receptor 2 (HER2) type and 30 five negative phenotype (5NP)) were selected from a series comprising 909 cases of breast cancer...
March 1, 2017: Journal of Clinical Pathology
https://www.readbyqxmd.com/read/28237784/differences-in-ki67-expressions-between-pre-and-post-neoadjuvant-chemotherapy-specimens-might-predict-early-recurrence-of-breast-cancer
#14
Emi Tokuda, Yoshiya Horimoto, Atsushi Arakawa, Takanori Himuro, Koji Senuma, Katsuya Nakai, Mitsue Saito
The prognosis of breast cancer patients not obtaining a pathological complete response (pCR) with neoadjuvant chemotherapy (NAC) is poorer than that of pCR patients. Identifying new prognostic factors for non-pCR patients is important because fractions of this population might benefit from novel adjuvant treatments currently under development. High Ki67 expression in remnant disease after NAC has been described as a poor prognostic factor. Studies have shown that a reduction in Ki67 expression is more often observed in good responders to chemotherapy...
February 22, 2017: Human Pathology
https://www.readbyqxmd.com/read/28220627/downregulation-of-mirna-141-in-breast-cancer-cells-is-associated-with-cell-migration-and-invasion-involvement-of-anp32e-targeting
#15
Ping Li, Tao Xu, Xin Zhou, Liangying Liao, Guolian Pang, Wan Luo, Lu Han, Jiankun Zhang, Xianyong Luo, Xiaobing Xie, Kuichun Zhu
MicroRNAs (miRNAs) regulate many cellular activities, including cancer development, progression, and metastasis. Some miRNAs are involved in breast cancer (BC) migration and invasion, thus affect patients' prognosis. Microarray analysis was performed to compare miRNA expression in BC tissues, and results confirmed by qPCR. BC cell migration and invasion were studied in vitro with MDA-MB-231 cells using microplate transwell assays. miRNA targeting was investigated using luciferase assays, qPCR, and Western blot analysis in cells with overexpression of miRNA mimics...
March 2017: Cancer Medicine
https://www.readbyqxmd.com/read/28218233/multi-institutional-study-of-nuclear-kifc1-as-a-biomarker-of-poor-prognosis-in-african-american-women-with-triple-negative-breast-cancer
#16
Angela Ogden, Chakravarthy Garlapati, Xiaoxian Bill Li, Ravi Chakra Turaga, Gabriela Oprea-Ilies, Nikita Wright, Shristi Bhattarai, Karuna Mittal, Ceyda Sönmez Wetherilt, Uma Krishnamurti, Michelle D Reid, Mildred Jones, Meenakshi Gupta, Remus Osan, Sonal Pattni, Ansa Riaz, Sergey Klimov, Arundhati Rao, Guilherme Cantuaria, Padmashree C G Rida, Ritu Aneja
Nuclear KIFC1 (nKIFC1) predicts worse outcomes in breast cancer, but its prognostic value within racially distinct triple-negative breast cancer (TNBC) patients is unknown. Thus, nKIFC1 expression was assessed by immunohistochemistry in 163 African American (AA) and 144 White TNBC tissue microarrays (TMAs) pooled from four hospitals. nKIFC1 correlated significantly with Ki67 in White TNBCs but not in AA TNBCs, suggesting that nKIFC1 is not merely a surrogate for proliferation in AA TNBCs. High nKIFC1 weighted index (WI) was associated with significantly worse overall survival (OS), progression-free survival (PFS), and distant metastasis-free survival (DMFS) (Hazard Ratios [HRs] = 3...
February 20, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28216075/-androgen-receptors-in-breast-cancer-expression-value-and-therapeutic-prospects
#17
REVIEW
Delphine Héquet, Slim Mzoughi, Roman Rouzier, Ernesto Guccione
Triple-negative (TN) breast cancer are characterized by lack of estrogen receptor (OR) and progesterone receptor (PR) expression, and the absence of overexpression of human epidermal growth factor receptor 2 (HER2). It is a heterogeneous group of tumors with a more pejorative prognosis than other subtypes of breast cancer. Androgen receptors (AR) are nuclear receptors whose expression varies from 80 to 85% of primary breast cancers and 60 to 75% of metastatic cancers. Among the TN breast cancers, the luminal androgen receptor (LAR) subtype expresses AR more frequently, up to 53% of the cases...
February 16, 2017: Bulletin du Cancer
https://www.readbyqxmd.com/read/28212549/the-prevalence-and-clinicopathological-features-of-breast-cancer-patients-with-hepatitis-b-virus-infection-in-china
#18
He Wu, Chunxia Zhao, Vishnu Prasad Adhikari, Linjie Lu, Jianbo Huang, Yuxian Wei, Qingqing Luo, Wei Dai, Yutuan Wu, Xin Li, Kainan Wu, Ling-Quan Kong
We performed a case-control study to investigate the prevalence and clinicopathological features of breast cancer patients with hepatitis B virus (HBV) infection in China. The clinical data for 2,796 female patients with newly diagnosed, primary breast cancer were evaluated. A total of 234 breast cancer patients with HBV infection (the case group; positive for hepatitis B surface antigen [HBsAg]) and 444 breast cancer patients without HBV infection (the control group; negative for HBsAg, hepatitis B surface antibody, hepatitis B envelope antigen, hepatitis B envelope antibody, and hepatitis B core antibody) were selected for study...
February 13, 2017: Oncotarget
https://www.readbyqxmd.com/read/28208155/pet-mr-in-invasive-ductal-breast-cancer-correlation-between-imaging-markers-and-histological-phenotype
#19
Onofrio Antonio Catalano, Gary Lloyd Horn, Alberto Signore, Carlo Iannace, Maria Lepore, Mark Vangel, Angelo Luongo, Marco Catalano, Constance Lehman, Marco Salvatore, Andrea Soricelli, Ciprian Catana, Umar Mahmood, Bruce Robert Rosen
BACKGROUND: Differences in genetics and receptor expression (phenotypes) of invasive ductal breast cancer (IDC) impact on prognosis and treatment response. Immunohistochemistry (IHC), the most used technique for IDC phenotyping, has some limitations including its invasiveness. We explored the possibility of contrast-enhanced positron emission tomography magnetic resonance (CE-FDG PET/MR) to discriminate IDC phenotypes. METHODS: 21 IDC patients with IHC assessment of oestrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor-2 (HER2), and antigen Ki-67 (Ki67) underwent CE-FDG PET/MR...
February 16, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28203454/mir-328-may-be-considered-as-an-oncogene-in-human-invasive-breast-carcinoma
#20
Alihossein Saberi, Amir Danyaei, Niloofar Neisi, Maryam Dastoorpoor, Mohammad Javad Tahmasbi Birgani
BACKGROUND: The recent investigations have rendered microRNAs (miRs) as a novel biomarker in cancer research. In fact, alteration in miR expression may be associated with tumor suppression, tumorigenesis, metastasis, and poor prognosis in human breast cancer (BC). OBJECTIVES: The aim of this clinical experimental study was to measure the miR-328 expression level in breast cancer tissues, at first. Then, we tried to find out any possible correlation between miR-328 and prognostic and predictive biomarkers in BC...
November 2016: Iranian Red Crescent Medical Journal
keyword
keyword
72753
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"